Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements

Abstract

Background: In this work, we aimed to establish a clinical target in the management of knee osteoarthritis (KOA) and to propose good clinical practice (GCP) statements for carrying out a treat-to-target strategy. Methods: A steering committee of seven experts had formulated a provisional set of recommendations that were exposed for discussion and modification to a technical expert panel (TEP) of 25 multidisciplinary experts from Europe, North America, South America and Asia. The level of evidence and strength of each recommendation was discussed. The TEP formulated overarching principles and GCP statements based on the level of agreement for each item with a vote using a 10-point numerical scale. Results: Two overarching principles and 10 GCP statements were formulated by the TEP. These GCP statements suggest: treatment should achieve clinical improvement bringing the patient to the Patient Acceptable Symptom State (PASS); pharmacological and nonpharmacological treatment should begin as early as possible, with an early diagnosis of symptomatic KOA; the patient should be evaluated every 3–6 months; risk factors of KOA progression should be identified and managed with patients at the beginning of the treatment and monitored regularly; treatment should be adapted according to patient phenotype and disease severity; healthy lifestyle must be promoted and monitored. The level of agreement average ranged from 8.7 to 9.6 on scale. Conclusions: The proposed overarching principles and GCP statements have the aim of involving patients, general practitioners and multidisciplinary specialists in sharing a therapeutic treat-to-target strategy for KOA management based on the best evidence and expert opinions.

Efficacy and safety of intra-articular injection of mesenchymal stem cells in the treatment of knee osteoarthritis

“…As a degenerative disease of the synovial joints, osteoarthritis (OA) is characterized by progressive joint destruction, with clinical manifestations of joint pain and dysfunction. [ 1 ] It is one of the most disabling diseases in the world, [ 2 – 4 ] with a global prevalence of 3.8% [ 5 ] that is increasing. [ 6 , 7 ] The incidence of the subtype of knee osteoarthritis is as high as 45%, which is much higher than that of other subtypes.…”

Comparison of 8-year knee osteoarthritis progression in 2 siblings: a case-based review

“…2). Supplemental searches were performed to expand on key topics identified in the original literature search, i.e., subchondral bone pathology [1], knee sleeves [2][3][4][5][19][20][21], bone marrow lesions [22][23][24][25][26], clinical risk factors for knee OA progression [27][28][29][30][31][32][33], OA phenotypes [34], nonpharmacological treatments for OA [35][36][37][38][39][40][41][42][43], and clinical practice guidelines for OA management [44].…”

“…Nonpharmacological treatments are a mainstay of OA management and can potentially help slow the progression of knee OA [35]. The most important nonpharmacological treatments used by the patients in the case studies are discussed.…”

Prospects for Using Colchicine in Medicine: New Evidence

“…Колхицин не относится к числу лекарственных препаратов, рекомендуемых для лечения остеоартрита (ОА) [34][35][36]. В то же время кристаллы основных фосфатов кальция, в первую очередь кристаллы гидроксиапатита, очень часто выявляются в хрящевой ткани у пациентов с ОА, и их обнаружение ассоциируется с гиперэкспрессией ИЛ1β, коррелирующей с тяжестью ОА [37][38][39].…”